Product Description
VB-421 is an anti-IGF-1R monoclonal antibody with a lead indication for thyroid eye disease (Sourced from: https://www.valenzabiotech.com/)
Mechanisms of Action: IGF Antagonist
Novel Mechanism: No
Modality: Antibody
Route of Administration: Subcutaneous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Pierre Fabre Laboratories
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 0: Autoimmune Disease Unspecified
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|